Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Newly Diagnosed Prostate Cancer Prior to Prostatectomy
NCT00672594Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 2006
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in prostate cancer (PCa), sponsored by Duke University. Primary endpoints: Change in Apoptotic Indices Before and After Treatment at 4 weeks and Change in Proliferation Indices Before and After Treatment at 4 weeks. Started Jul 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00672594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00672594.